Toll Brothers Announces New Luxury Home Community Coming Soon to Magnolia, Texas
MAGNOLIA, Texas, May 16, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, announced its newest Houston-area community, Toll Brothers at Wildtree, is coming soon to Magnolia, Texas. This highly anticipated community will feature modern one- and two-story home designs on expansive 60-foot-wide home sites. Construction is underway, and sales are expected to begin in late 2025.
Toll Brothers at Wildtree will offer an elevated collection of versatile floor plans up to 3,600+ square feet. The homes will feature contemporary architecture with unique details such as cathedral ceilings and spiral staircases, as well as unrivaled options for personalization. Residents will be just steps away from the future amenity center within the Wildtree master plan including a clubhouse, a resort-style pool, ample greenspace with scenic walking and biking trails, and much more. The new Toll Brothers homes are expected to be priced starting in the mid-$500,000s.
'Our new Toll Brothers at Wildtree community will offer residents the rare opportunity to build a new home within the well-established and highly desirable Magnolia area,' said Brian Murray, Division President of Toll Brothers in Houston. 'With large, open floor plans and unrivaled personalization options through the Toll Brothers Design Studio experience, this resort-style community will set a new standard for luxury living in Magnolia.'
Residents will enjoy convenient access to Texas State Highway 249 and the Grand Parkway, making travel to and from the community effortless. The community is served by the highly rated Magnolia Independent School District, including Magnolia Parkway Elementary, Magnolia Junior High School, and Magnolia West High School.
Toll Brothers customers will experience one-stop shopping at the Toll Brothers Design Studio. The state-of-the-art Design Studio allows customers to choose from a wide array of selections to personalize their dream home with the assistance of Toll Brothers professional Design Consultants.
Additional Toll Brothers new home communities in this area include Toll Brothers at NorthGrove, Toll Brothers at Woodson's Reserve, and Toll Brothers at Woodhavyn.
Toll Brothers at Wildtree will be located at 4919 Pinestraw Valley Way in Magnolia. For more information, call (833) 289-8655 or visit TollBrothers.com/Houston.
About Toll Brothers
Toll Brothers, Inc., a Fortune 500 Company, is the nation's leading builder of luxury homes. The Company was founded 58 years ago in 1967 and became a public company in 1986. Its common stock is listed on the New York Stock Exchange under the symbol 'TOL.' The Company serves first-time, move-up, empty-nester, active-adult, and second-home buyers, as well as urban and suburban renters. Toll Brothers builds in over 60 markets in 24 states: Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Indiana, Maryland, Massachusetts, Michigan, Nevada, New Jersey, New York, North Carolina, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, and Washington, as well as in the District of Columbia. The Company operates its own architectural, engineering, mortgage, title, land development, smart home technology, and landscape subsidiaries. The Company also develops master-planned and golf course communities as well as operates its own lumber distribution, house component assembly, and manufacturing operations.
Toll Brothers has been one of Fortune magazine's World's Most Admired Companies™ for 10+ years in a row, and in 2024 the Company's Chairman and CEO Douglas C. Yearley, Jr. was named one of 25 Top CEOs by Barron's magazine. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com.
From Fortune, ©2025 Fortune Media IP Limited. All rights reserved. Used under license.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Stocks Climb on Hopes of Easing US-China Trade Tensions
The S&P 500 Index ($SPX) (SPY) today is up +0.21%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.11%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.46%. June E-mini S&P futures (ESM25) are up +0.21%, and June E-mini Nasdaq futures (NQM25) are up +0.42%. Stock indexes recovered from early losses and are moving higher today, with the Nasdaq 100 reaching a 3 1/2-month high. Stocks are climbing on hopes that trade tensions will ease between the US and China after China's state media Xinhua News Agency reported that US President Trump and Chinese President Xi Jinping spoke by telephone today. President Xi agreed to more talks with Mr. Trump and urged the US to remove 'negative' measures that have roiled trade tensions between the two countries. The Chinese president also said the countries should work to reduce misunderstandings and that Trump was welcome to visit China. Stocks also garnered support from today's economic news that showed the US trade deficit in April shrank to a 20-month low, a positive factor for Q2 GDP. Stocks were under early pressure today on concerns about the US labor market after weekly jobless claims unexpectedly rose to a 7-3/4 month high. Also, today's downward revision to US Q1 nonfarm productivity and upward revision to Q1 unit labor costs were bearish for stocks. In addition, higher bond yields are negative for stocks as the 10-year T-note yield is up +3 bp to 4.39% as it rebounded from a 4-week low of 4.31% on negative carryover from a slide in 10-year German bunds after ECB President Lagarde said the ECB was nearing the end to its rate cutting cycle. US weekly initial unemployment claims unexpectedly rose +8,000 to a 7-3/4 month high of 247,000, showing a weaker labor market than expectations of a decline to 235,000. The US Apr trade deficit shrank to a 20-month low of -$61.6 billion, narrower than expectations of -$66.0 billion. US Q1 nonfarm productivity was revised lower to -1.5% from -0.8%. Q1 unit labor costs were revised upward to 6.6% from the previously reported 5.7%. Comments Wednesday evening from Minneapolis Fed President Kashkari signal he favors keeping interest rates steady when he said, 'The economy is seeming like it's pretty resilient so far, and so for me right now is the time to get data, see how the tariff negotiations shake out before we reach any firm conclusions about the direction of interest rates.' The markets are discounting the chances at 1% for a -25 bp rate cut at the next FOMC meeting on June 17-18. The markets this week will focus on any fresh trade or tariff news. On Friday, May nonfarm payrolls are expected to climb +125,000, and the May unemployment rate is expected to remain unchanged at 4.2%. Finally, May average hourly earnings are expected to rise +0.3% m/m and +3.7% y/y. Overseas stock markets today are mixed. The Euro Stoxx 50 is up +0.02%. China's Shanghai Composite climbed to a 1-1/2 week high and closed up +0.23%. Japan's Nikkei Stock 225 closed down -0.51%. Interest Rates September 10-year T-notes (ZNU2 5) today are down -5 ticks. The 10-year T-note yield is up +3.0 bp to 4.385%. Sep T-notes today fell from a 4-week high, and the 10-year T-note yield rose from a 4-week low of 4.310% and is moving higher. T-notes gave up early gains today and turned lower as stocks rallied on hopes of easing US-Chian trade tensions after the Xinhua news agency reported that President Trump and President Xi Jinping spoke by telephone today. T-notes also have a negative carryover from a slide in 10-year German bunds on hawkish comments from ECB President Lagarde, who said the ECB is nearing the end of its rate-cutting cycle. In addition, T-notes fell after today's news that showed US Q1 nonfarm productivity was revised downward and Q1 unit labor costs were revised higher. T-notes today initially moved higher when weekly US jobless claims unexpectedly rose to a 7-3/4 month high, a sign of labor market weakness and a dovish factor for Fed policy. Also, an easing in inflation expectations is bullish for T-notes after the US 10-year breakeven inflation rate fell to a 3-week low today at 2.297%. European government bond yields today are moving higher. The 10-year German bund yield rebounded from a 4-week low of 2.476% and is up +5.8 bp to 2.587%. The 10-year UK gilt yield rebounded from a 3-1/2 week low of 4.554% and is up +2.1 bp to 4.628%. Eurozone Apr PPI fell -2.2% m/m and rose +0.7% y/y, weaker than expectations of -2.1% m/m and +1.1% y/y. German Apr factory orders unexpectedly rose +0.6% m/m, stronger than expectations of -1.5% m/m. The ECB, as expected, cut the deposit facility rate by -25 bp to 2.00% from 2.25% and said, 'Inflation is currently at around the Governing Council's 2% medium-term target.' ECB President Lagarde said risks to growth 'tilted to the downside' as recent survey data points to weaker near-term prospects for the Eurozone economy. However, a stronger labor market and rising incomes will help the economy, and she wouldn't exclude further upward revisions to growth. She added that the ECB is getting toward the end of its rate cut cycle with today's rate cut. Swaps are discounting the chances at 42% for a -25 bp rate cut by the ECB at the July 24 policy meeting. US Stock Movers The strength of chip makers is supportive of the broader market. Micron Technology (MU) is up more than +4% to lead gainers in the Nasdaq 100. Also, ARM Holdings NV (ARM), Texas Instruments (TXN), ASML Holding NV (ASML), Applied Materials (AMAT), and Microchip Technology (MCHP) are up more than +1%. In addition, Lam Research (LRCX) and Analog Devices (ADI) are up more than +0.90%. Mining stocks are climbing today as the price of gold rose to a 4-week high and silver prices soared to a 13-year high. As a result, Freeport-McMoRan (FCX) is up more than +4%, and Anglogold Ashanti Plc (AU) is up more than +1%. MongoDB (MDB) is up more than +15% after reporting Q1 adjusted EPS of $1.06, well above the consensus of 67 cents, and raising its 2026 adjusted EPS forecast to $2.94-$3.12 from a previous estimate of $2.44-$2.62, stronger than the consensus of $2.60. Five Below (FIVE) is up more than +7% after reporting Q1 comparable sales rose +7.1%, better than the consensus of +6.37%, and forecast 2026 comparable sales will climb +3% to +5%, the midpoint above the consensus of +3.78%. Dollar Tree (DLTR) is up more than +7% to lead gainers in the S&P 500 after JPMorgan Chase upgraded the stock to overweight from neutral with a price target of $111. Verint Systems (VRNT) is up more than +6% after reporting Q1 adjusted EPS of 29 cents, better than the consensus of 19 cents. Brown-Forman (BF.B) is down more than -17% to lead losers in the S&P 500 after reporting Q4 net sales of $894 million, well below the consensus of $968.4 million. PVH Corp (PVH) is down more than -17% after cutting its 2026 adjusted EPS forecast to $10.75-$1.00 from a previous forecast of $12.40-$12.75, well below the consensus of $12.46. Ciena Corp (CIEN) is down more than -11% after reporting Q2 adjusted EPS of 42 cents, weaker than the consensus of 52 cents. Tesla (TSLA) is down more than -3% to lead losers in the Nasdaq 100, adding to Wednesday's -4% slide, after reporting its May vehicle shipments from China fell -15% y/y to 61,662 units, the eighth straight monthly decline. Costco Wholesale (COST) is down more than -2% after reporting May total comparable sales rose +4.3%, weaker than the consensus of +4.7% Procter & Gamble (PG) is down more than -1% to lead losers in the Dow Jones Industrials after announcing it expects to take a $1.6 billion charge over the next two years as it cuts its workforce by 7,000 or 15%. Earnings Reports (6/5/2025) Broadcom Inc (AVGO), Brown-Forman Corp (BF/B), Ciena Corp (CIEN), Docusign Inc (DOCU), Lululemon Athletica Inc (LULU), Toro Co/The (TTC), Vail Resorts Inc (MTN).
Globe and Mail
3 hours ago
- Globe and Mail
Broadcom Slides on Solid Earnings, AI Outlook Still Strong
[content-module:CompanyOverview|NASDAQ:AVGO] Given Broadcom's (NASDAQ: AVGO) explosive up moves after its past two earnings releases, many investors were likely hopeful to see fireworks again on June 5. The chip giant's price action would disappoint, but it should not discourage investors. Broadcom's fiscal Q2 earnings were solid by all accounts. Additionally, management provided some helpful commentary, despite deflecting some of the analysts' most pressing questions. Broadcom's Financials and Guidance Were Right on the Money Both on the top and bottom lines, Broadcom's fiscal Q2 2025 results came in almost exactly in line with expectations. The company's revenues of $15 billion resulted in growth of above 20%. This barely beat growth expectations of just under 20%. The company's adjusted earnings per share of $1.58 beat expectations of $1.57. The figure resulted in an earnings growth rate of under 44%, surpassing estimates of just under 43% growth. In terms of guidance, the company forecasted revenue of approximately $15.8 billion for fiscal Q3. This implies a growth rate of 21%, a sprinkle above estimates. Broadcom also predicted its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin to come in at 'at least' 66%. This implies a small contraction from the 67% figure it achieved in fiscal Q2. Tan's Takes: Business Remains Booming, but No Seismic Updates Revealed Chief Executive Officer (CEO) Hock Tan said the company's three hyper-scale customers and four potential ones are 'unwavering' in their AI investment plans. This is true even with the current macroeconomic challenges. The company backed this up by providing AI semiconductor guidance of $5.1 billion in fiscal Q3, which would be an increase of 60%. Additionally, the company confirmed that, based on current visibility, it expects this growth rate to continue through fiscal 2025 and fiscal 2026. This is a particularly positive sign, indicating that demand is not expected to slow down anytime soon. However, to the chagrin of analysts, Tan firmly refused to give insights on when revenue contributions for its prospective customers might come. Tan said the company would likely not provide updates on this until sometime in fiscal 2026. He also refused to provide any type of updates to the company's serviceable addressable market (SAM) estimates. Tan provided notable news on the company's infrastructure software segment, particularly when it came to moving VMware customers from perpetual licenses to subscriptions. This has been key to the company's software success. Shifting customers to subscriptions boosts recurring revenue. It also upsells them to a more comprehensive package. Now, 87% of the company's 10,000 largest VMware customers have transitioned to the subscription model, a significant increase from just 70% a quarter ago. Tan added that two-thirds of the overall customer base have transitioned, moderately up from 60% last quarter. Another interesting highlight was the company's AI networking revenue. This came in strong at 40% of total AI revenue, the same as the prior quarter. The company expected this figure to drop closer to 30%, but it hasn't. The company continues to guide that, on average, AI networking will make up around 30% of total AI revenue over time. Tan said the company was experiencing a positive surprise in AI networking. He said that 'scale-up' data center server architectures are increasingly adopting Ethernet. Scale-up refers to when server racks pack compute chips more densely. Meanwhile, "scale-out" architectures increase computing capacity by adding more server racks across a data center. Scale-up architecture requires 5 to 10 times higher switch density than scale-out architectures. This creates a significant need for the company's new high-capacity Tomahawk 6 switch chips, which offer leading-edge port density and bandwidth. Broadcom Shares Fall Moderately, But Remain Barely Off All-Time Highs [content-module:Forecast|NASDAQ:AVGO] By the end of after-hours trading, shares were down around 4%. Broadcom's share drop shows mild disappointment in its financials. It is also indicative of the fact that there was no groundbreaking news in the call. Still, it's hard to be overly disappointed. The stock was trading very close to an all-time high before the result. At the conclusion of after-hours trading, shares were down less than 5% from their all-time closing high. The market will want to see much larger beats to send shares soaring, as in past quarters. Getting more information around contributions from prospective AI-chip customers could also do the trick. Potential analyst upgrades may also propel shares higher as information from these earnings gets digested further. Overall, things at Broadcom are going according to plan. Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
Globe and Mail
8 hours ago
- Globe and Mail
Hims & Hers Stock Is Soaring Again. But Should You Buy the Stock?
Many companies have failed to disrupt the complicated U.S. healthcare market. Hims & Hers (NYSE: HIMS) may finally be succeeding in cracking the code. The online telehealth platform focuses on circumventing the insurance market; its business of selling affordable medications directly to individuals is growing like a weed, and expects to generate $6.5 billion in revenue by 2030. It has had a tumultuous start to 2025, as Hims & Hers waged a battle to sell new weight loss medications on its online marketplace. Now, with momentum back on its side, the stock is up 118% year to date and 446% in the last five years. Let's take a deeper look at this company, and see whether you might want to buy Hims & Hers stock for your portfolio now. Disrupting the healthcare market Hims & Hers' model is simple. It has two separate web platforms -- Hims for men and Hers for women -- that sell medications and deliver to customers' front doors. It began with sexual health, but has moved into dermatology, hair loss, mental health, and now weight loss medications. A key to its success has been avoiding the insurance market with products that don't break the bank. Customers loathe dealing with health insurers in the United States, and sometimes would rather not use insurance at all. Plus, some of these products aren't covered by insurance. This strategy has helped the company close in on over $2 billion in projected revenue in 2025. To keep up this impressive growth, Hims & Hers wants to offer weight loss medications, which have been a blockbuster set of drugs for the pharmaceutical market. For a while the popularity of these drugs, such as Novo Nordisk 's Wegovy, left them in short supply; that allowed third parties such as Hims & Hers to produce them as a compounding pharmacy and sell them at much cheaper prices. This ended up generating $200 million of Hims & Hers' $1.4 billion in 2024 revenue. But with the shortage of Wegovy over and the compounding pharmacy exception ended, the company's weight-loss business was at a major turning point. Luckily, at the end of April Hims & Hers announced a partnership with Novo Nordisk that seems to resolve this issue: It gives Hims & Hers the ability to sell Wegovy directly on its platform. Hims & Hers is not an exclusive supplier of the drug -- or any drugs on its marketplaces, to be fair -- but it hopes to use its subscription business model, marketing expertise, and simplified user proposition to drive sales for Novo Nordisk in the huge obesity-care market. Going abroad and personalization Besides weight loss drugs, Hims & Hers has more ambitions to reach its goal of $6.5 billion in revenue by 2030. Just recently, the company announced its intent to acquire European competitor Zava so it could expand its telehealth service to Europe. The acquisition will add a platform with 1.3 million active customers in the U.K., Germany, France, and Ireland. It makes sense that Hims & Hers can supercharge growth for the platform with its plethora of medications offered to customers, keen marketing skills, and subscription-based selling model. Over the long run, Hims & Hers aims to make healthcare for its customers more personalized. This includes unique drug combinations, its own outsourcing facility, and at-home testing capabilities. Details remain sparse, but the vision is clear: disrupting more and more of the trillions of dollars spent on healthcare by building a business that people actually enjoy interacting with. This is why 2.4 million active customers use Hims & Hers today. HIMS Gross Profit Margin data by YCharts. Should you buy Hims & Hers stock? A revenue goal of $6.5 billion seems well within reach by 2030. Hims & Hers is only at 2.4 million active customers, and there are tens of millions of people in the United States alone who could start using or switch to one of its telehealth platforms. Add on the Zava acquisition in Europe, and the runway for growth gets even larger. The company has an impressive gross profit margin of 77%, which should lead to high levels of profitability at scale. On $6.5 billion in future revenue, it could very well post a net profit margin of over 20%, and achieve $1.5 billion in bottom-line profits and free cash flow. A 20% profit margin is easily achievable because of its high gross margins and the fact it currently spends 40% of revenue on marketing today, a figure that has come down over time and should come down even more as Hims & Hers keeps scaling. However, Hims & Hers has played fast and loose with laws and regulations in the past. It sold weight loss drugs when the legality of doing so was unclear, and although that dispute seems to have been resolved, management could easily start playing with fire again and burn its reputation as a trusted provider of medications. Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today, Hims & Hers has a market cap of $12.3 billion. You might think it's overvalued because of the stock's recent run-up in price, but the numbers show that patient investors could be rewarded by holding for the long term. A $12.3 billion market cap is only around 8 times my 2030 earnings estimate of $1.5 billion, which would be a dirt cheap price-to-earnings (P/E) ratio for a fast-growing company compared to the current market cap. Most likely, the stock will be valued at a higher multiple than 8, meaning that the stock will be higher in five years. It doesn't come without risks, but if you're a growth investor, you might love Hims & Hers stock for its long-term potential. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
